NIH R01 · 2025
Degradomics of proteolytic mechanisms in post-traumatic osteoarthritis
Osteoarthritis (OA) is usually diagnosed when joint damage is well under way. Its early detection and treatment continue to be elusive, requiring greater knowledge of pathogenic processes and potential drug targets active early in the disease. Proteolytic destruction of cartilage extracellular matrix (ECM) is a hallmark of OA that contributes to loss of joint function; proteolytic products provoke further catabolism, drive inflammation and incite pain. Despite the interest in proteases as drug targets in OA, the scale, timeline and impact of proteolysis and the contributing proteases are largely unknown. The few biomarkers that detect proteolytic cleavages in the joint are widely used, but…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.